GB2520897B - Compositions and methods for treating cutaneous scarring - Google Patents

Compositions and methods for treating cutaneous scarring Download PDF

Info

Publication number
GB2520897B
GB2520897B GB1505972.8A GB201505972A GB2520897B GB 2520897 B GB2520897 B GB 2520897B GB 201505972 A GB201505972 A GB 201505972A GB 2520897 B GB2520897 B GB 2520897B
Authority
GB
United Kingdom
Prior art keywords
compositions
methods
treating cutaneous
cutaneous scarring
scarring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB1505972.8A
Other languages
English (en)
Other versions
GB2520897A (en
GB201505972D0 (en
Inventor
Lander Cynthia
Brophy Colleen
Peterson Caryn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Moerae Matrix Inc
Original Assignee
Moerae Matrix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moerae Matrix Inc filed Critical Moerae Matrix Inc
Publication of GB201505972D0 publication Critical patent/GB201505972D0/en
Publication of GB2520897A publication Critical patent/GB2520897A/en
Application granted granted Critical
Publication of GB2520897B publication Critical patent/GB2520897B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B33—ADDITIVE MANUFACTURING TECHNOLOGY
    • B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
    • B33Y80/00—Products made by additive manufacturing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
GB1505972.8A 2012-09-10 2013-09-10 Compositions and methods for treating cutaneous scarring Expired - Fee Related GB2520897B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261699160P 2012-09-10 2012-09-10
US13/829,876 US20140072613A1 (en) 2012-09-10 2013-03-14 Compositions and Methods for Treating Cutaneous Scarring
PCT/US2013/059060 WO2014040074A2 (en) 2012-09-10 2013-09-10 Compositions and methods for treating cutaneous scarring

Publications (3)

Publication Number Publication Date
GB201505972D0 GB201505972D0 (en) 2015-05-20
GB2520897A GB2520897A (en) 2015-06-03
GB2520897B true GB2520897B (en) 2020-07-01

Family

ID=50233502

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1505972.8A Expired - Fee Related GB2520897B (en) 2012-09-10 2013-09-10 Compositions and methods for treating cutaneous scarring

Country Status (14)

Country Link
US (1) US20140072613A1 (enExample)
EP (1) EP2892546A4 (enExample)
JP (1) JP6247692B2 (enExample)
KR (1) KR102040710B1 (enExample)
CN (1) CN105120886A (enExample)
AU (1) AU2013312120B2 (enExample)
CA (1) CA2884264A1 (enExample)
GB (1) GB2520897B (enExample)
HK (2) HK1210422A1 (enExample)
MX (1) MX368878B (enExample)
NZ (1) NZ705743A (enExample)
RU (2) RU2705211C2 (enExample)
SG (1) SG11201501818VA (enExample)
WO (1) WO2014040074A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3643782A1 (en) 2008-02-11 2020-04-29 Phio Pharmaceuticals Corp. Modified rnai polynucleotides and uses thereof
EP2342340A1 (en) 2008-09-22 2011-07-13 Rxi Pharmaceuticals Corporation Rna interference in skin indications
US9074211B2 (en) 2008-11-19 2015-07-07 Rxi Pharmaceuticals Corporation Inhibition of MAP4K4 through RNAI
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US9095504B2 (en) 2010-03-24 2015-08-04 Rxi Pharmaceuticals Corporation RNA interference in ocular indications
WO2011119852A1 (en) 2010-03-24 2011-09-29 Rxi Pharmaceuticals Corporation Reduced size self-delivering rnai compounds
CA2794189C (en) 2010-03-24 2022-01-11 Rxi Pharmaceuticals Corporation Rna interference in dermal and fibrotic indications
EP2943564B1 (en) 2013-01-09 2026-03-25 International Stem Cell Corporation Sl327 for use in skin regeneration
JP6772062B2 (ja) * 2013-12-02 2020-10-21 フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． 癌の免疫療法
EP3188799B1 (en) 2014-09-05 2022-07-06 Phio Pharmaceuticals Corp. Methods for treating aging and skin disorders using nucleic acids targeting tyr or mmp1
KR20170102900A (ko) 2015-01-08 2017-09-12 모레 매트릭스 인코포레이티드 Mk2 저해제 펩타이드의 제형
CA2978941A1 (en) 2015-03-12 2016-09-15 Moerae Matrix, Inc. Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same
CN104689301A (zh) * 2015-03-27 2015-06-10 吴开刚 一种祛除妊娠纹的药物及其制备方法
US10709702B2 (en) 2015-10-08 2020-07-14 Amd Therapeutics Llc Treatment of skin disorders by topical administration of VEGF inhibitors
CN105709270B (zh) * 2016-03-18 2019-01-01 中国科学院长春应用化学研究所 一种用于干细胞治疗的水凝胶敷料
JP6815782B2 (ja) * 2016-07-29 2021-01-20 小林製薬株式会社 α−ＳＭＡ産生抑制剤
EP3532071A4 (en) * 2016-10-30 2020-09-02 Sirnaomics, Inc. PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE TO ACTIVATE HUMAN FIBROBLAST AND MYOFIBROBLAST APOPTOSIS
KR101921727B1 (ko) * 2016-12-28 2018-11-23 주식회사 제네웰 실리콘 수지 조성물, 이의 제조방법 및 이를 포함하는 흉터 치료제
JP7167059B2 (ja) 2017-04-19 2022-11-08 フィオ ファーマシューティカルズ コーポレーション 核酸化合物の局所送達
EP3675874B1 (en) * 2017-09-01 2023-11-29 Excel Med, LLC Pharmaceuticals composition for treating keloid and uses thereof
US10485755B1 (en) * 2018-02-05 2019-11-26 Wade Cheng Formulation and method for treatment of non-acne scars
EP3749750A1 (en) * 2018-02-09 2020-12-16 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Means and methods for monitoring scar development
CN108451981B (zh) * 2018-04-21 2019-07-23 江西汉氏联合干细胞科技有限公司 使用皮肤间充质干细胞治疗系统性硬化症
WO2019222520A1 (en) * 2018-05-16 2019-11-21 The Board Of Trustees Of The Leland Stanford Junior University Controlled hydrogel delivery of focal adhesion kinase inhibitor for decreased scar formation
CN111558128A (zh) * 2019-03-26 2020-08-21 华中科技大学同济医学院附属协和医院 一种载瘢痕修复药物的可溶性微针阵列及制备方法
US20220202827A1 (en) * 2019-04-08 2022-06-30 The General Hospital Corporation Enhancement of Melanocyte Migration Using ROCK Inhibitors
US11904000B2 (en) 2019-05-06 2024-02-20 Brown University Compositions and methods to enhance cutaneous wound healing
WO2020227738A1 (en) * 2019-05-09 2020-11-12 The University Of Chicago Novel material for skin wound closure and scar prevention
US20210000910A1 (en) 2019-07-03 2021-01-07 Jysk Skin Solutions Pte Ltd Topical compositions
RU2712183C1 (ru) * 2019-09-30 2020-01-24 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ лечения пациентов с рубцовыми поражениями кожи
CN110917179B (zh) * 2019-12-19 2021-04-27 温州医科大学附属第一医院 一种抗疤痕硅凝胶贴及其制备方法
WO2021145699A1 (ko) * 2020-01-17 2021-07-22 한국생명공학연구원 콜히친을 포함하는 피부 질환 치료용 조성물
US12360428B2 (en) * 2020-04-13 2025-07-15 Massachusetts Institute Of Technology Melanin-peptide-based photonic materials
CN112425560A (zh) * 2020-10-27 2021-03-02 纳肽得有限公司 皮肤增生性瘢痕动物模型及其构建方法
CN113143524A (zh) * 2021-04-13 2021-07-23 王伟 一种用于构建微创兔膝关节炎模型的穿刺系统
US20240226233A1 (en) * 2021-05-03 2024-07-11 L&C Bio Co., Ltd. Composition comprising zag-derived peptide for improving scars and keloids
CA3220398A1 (en) * 2021-07-30 2023-02-02 Geoffrey Gurtner Mechanotransduction disruption mediation in skin grafting methods and compositions for use in practicing the same
EP4464694A4 (en) 2022-01-14 2026-04-01 Shanghai Hansoh Biomedical Co Ltd POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE
US12083204B2 (en) 2022-06-02 2024-09-10 L'oreal Topical composition for homeostatic delivery of nitric oxide and uses thereof
KR102696817B1 (ko) * 2023-07-06 2024-08-21 주식회사 아루다 히알루론산, 프로테오글리칸, 글리코사미노글리칸, 아텔로콜라겐, 베타글루칸, 유비퀴논 및 비타민 e를 포함하는 에스테틱 조성물 및 이의 제조 방법
CN117304303B (zh) * 2023-07-14 2024-07-05 杭州恩和生物科技有限公司 纤连蛋白截短片段、组合物及用途
WO2026076246A1 (en) * 2024-10-03 2026-04-09 Frontier Bio Corporation Methods and systems for generating vascularized neurospheres
KR20260090760A (ko) * 2024-12-09 2026-06-17 온바이오 주식회사 봉합자국 및 흉터를 최소화 할 수 있는 재건 미용 시술방법

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008085191A1 (en) * 2007-01-10 2008-07-17 Purdue Research Fundation Polypeptide inhibitors of hsp27 kinase and uses therefor
US20080293640A1 (en) * 2007-01-10 2008-11-27 Arizona Board of Regents, A body Corporate, of the State of Arizona, acting for and on behalf of Polypeptide inhibitors of HSP27 kinase and uses therefor
US20100098760A1 (en) * 2007-01-10 2010-04-22 Alyssa Panitch Polypeptide for treating or preventing adhesions
WO2011160055A2 (en) * 2010-06-18 2011-12-22 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Hair follicle neogenesis
WO2012082950A2 (en) * 2010-12-14 2012-06-21 University Of Rochester Chimeric fibronectin matrix mimetics and uses thereof
WO2012106508A1 (en) * 2011-02-02 2012-08-09 Pfizer Inc. Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2200557C1 (ru) * 2001-11-23 2003-03-20 Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. акад. С.Н.Федорова Способ лечения гипертрофических и келоидных рубцов
WO2008109794A2 (en) 2007-03-08 2008-09-12 Tufts Medical Center The role of the mk2 pathway in treating fibrosis and scarring
DK2185698T3 (en) * 2007-08-07 2015-07-27 Purdue Research Foundation Kinase Inhibitors and Uses thereof
WO2009038783A1 (en) * 2007-09-19 2009-03-26 Surmodics, Inc. Biocompatible foams, systems, and methods
EP2252690A2 (en) * 2007-12-21 2010-11-24 Coda Therapeutics, Inc. Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
US9327008B2 (en) 2008-12-10 2016-05-03 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
WO2010098760A1 (en) * 2009-02-26 2010-09-02 Hewlett-Packard Development Company, L.P. Void pantographs and methods for generating the same
US9890195B2 (en) 2009-07-27 2018-02-13 Purdue Research Foundation MK2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008085191A1 (en) * 2007-01-10 2008-07-17 Purdue Research Fundation Polypeptide inhibitors of hsp27 kinase and uses therefor
US20080293640A1 (en) * 2007-01-10 2008-11-27 Arizona Board of Regents, A body Corporate, of the State of Arizona, acting for and on behalf of Polypeptide inhibitors of HSP27 kinase and uses therefor
US20100098760A1 (en) * 2007-01-10 2010-04-22 Alyssa Panitch Polypeptide for treating or preventing adhesions
WO2011160055A2 (en) * 2010-06-18 2011-12-22 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Hair follicle neogenesis
WO2012082950A2 (en) * 2010-12-14 2012-06-21 University Of Rochester Chimeric fibronectin matrix mimetics and uses thereof
WO2012106508A1 (en) * 2011-02-02 2012-08-09 Pfizer Inc. Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Biochemical and Biophysical Research Communications, Vol. 382, No. 3, 2009, Lopes et. al., "Inhibition of HSP27 phosphorylation by a cell-permeant MAPKAP Kinase 2 inhibitor", pp. 535-539. *

Also Published As

Publication number Publication date
MX368878B (es) 2019-10-21
NZ705743A (en) 2018-08-31
GB2520897A (en) 2015-06-03
CN105120886A (zh) 2015-12-02
GB201505972D0 (en) 2015-05-20
KR102040710B1 (ko) 2019-11-05
WO2014040074A3 (en) 2014-06-26
CA2884264A1 (en) 2014-03-13
WO2014040074A2 (en) 2014-03-13
EP2892546A4 (en) 2016-07-13
HK1210422A1 (en) 2016-04-22
US20140072613A1 (en) 2014-03-13
SG11201501818VA (en) 2015-04-29
RU2015113011A (ru) 2016-11-10
EP2892546A2 (en) 2015-07-15
RU2705211C2 (ru) 2019-11-06
RU2019126644A (ru) 2019-09-19
HK1210414A1 (en) 2016-04-22
JP6247692B2 (ja) 2017-12-13
AU2013312120B2 (en) 2018-04-19
KR20150100615A (ko) 2015-09-02
JP2015533798A (ja) 2015-11-26
AU2013312120A1 (en) 2015-03-26
MX2015003075A (es) 2016-02-05

Similar Documents

Publication Publication Date Title
SG11201501818VA (en) Compositions and methods for treating cutaneous scarring
IL238416A0 (en) Preparations and methods for the treatment of diseases caused by protein pathology
SMT201700595T1 (it) Composizioni e metodi per trattare il cancro
IL227429A0 (en) The components and methods of cancer treatment
IL234829A0 (en) Methods and preparations for treating inflammation
PT2920149T (pt) Compostos de 3-aminocicloalquil como inibidores de ror-gama-t e utilizações dos mesmos
DK3292875T3 (en) Compositions and methods for treating diseases
EP3077049A4 (en) Compositions and methods for treating vitiligo
PL2838888T3 (pl) Tiadiazolidynodiony jako inhibitory gsk-3
EP2590674A4 (en) COMPOSITIONS AND METHODS FOR INFLUENZA TREATMENT
IL232648A0 (en) Preparations and methods for treating glioma
IL225483A0 (en) The compositions and methods for the treatment of neoplasia
EP3065550A4 (en) Methods and compositions for treating sepsis
SG11201510300RA (en) Compositions and methods for treating skin
IL229231A0 (en) Preparations and methods for the treatment of cancer
GB201315350D0 (en) Methods and compositions
GB201315347D0 (en) Methods and compositions
IL238403A0 (en) Methods and preparations for the treatment of progesterone-dependent conditions
GB201222820D0 (en) Woolscouring method and composition
SI2617412T1 (sl) Sestavek za topično zdravljenje
LT2863931T (lt) Kompozicijos, skirtos panaudoti žaizdų gydymui
EP2887967A4 (en) COMPOSITIONS AND METHODS FOR TREATING HEPATOCELLULAR CANCER
GB201206859D0 (en) Method and composition
ZA201500172B (en) Plant-disease-control composition and plant-disease-control method
ZA201408732B (en) Composition and methods for treating wounds

Legal Events

Date Code Title Description
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1210414

Country of ref document: HK

PCNP Patent ceased through non-payment of renewal fee

Effective date: 20201001

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1210414

Country of ref document: HK